IMA-203CD8 is under clinical development by Immatics and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase II drugs for Bile Duct Cancer (Cholangiocarcinoma) have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IMA-203CD8’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMA-203CD8 overview
IMA-203CD8 is under development for the treatment of multiple solid tumors including uveal melanoma, synovial sarcoma, hepatocellular carcinoma, ovarian cancer, uterine cancer, squamous non-small cell lung cancer, head and neck cancer, triple-negative breast cancer, small-cell lung cancer, kidney cancer (renal cell cancer), bile duct cancer (cholangiocarcinoma), esophageal cancer, bladder carcinoma, thymic carcinoma, rhabdomyosarcoma, fibrosarcoma. and head and neck cancer. It is administered through intravenous route. The drug candidate consists of IMA203-engineered T cells targeting PRAME co-transduced with CD8αβ T cell co-receptor that plays an important role during T cell antigen recognition and T cell activation. The therapeutic candidate is developed based on ACTengine platform technology.
Immatics overview
Immatics is a biopharmaceutical company focused on the development of T cell immunotherapies to fight against cancer. The company is headquartered in Tubingen, Baden-Wurttemberg, Germany.
For a complete picture of IMA-203CD8’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
